瑞银发表报告指,百济神州(06160.HK) 旗下百悦泽(Brukinsa)于一线治疗套细胞淋巴瘤(MCL)的正面三期数据,提供潜在无化疗选项。报告指,百济神州公布全球三期MANGROVE试验评估Brukinsa联合Rituximab用于一线治疗MCL的正面顶线数据。此无化疗方案达到了无进展生存期(PFS)的主要终点,与Bendamustine联合Rituximab(BR)相比,疾病进展或死亡的...
Source Link瑞银发表报告指,百济神州(06160.HK) 旗下百悦泽(Brukinsa)于一线治疗套细胞淋巴瘤(MCL)的正面三期数据,提供潜在无化疗选项。报告指,百济神州公布全球三期MANGROVE试验评估Brukinsa联合Rituximab用于一线治疗MCL的正面顶线数据。此无化疗方案达到了无进展生存期(PFS)的主要终点,与Bendamustine联合Rituximab(BR)相比,疾病进展或死亡的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.